NEWCASTLE, UK - Sep 14, 2018 - QuantuMDx Group Ltd, the UK-based multinational molecular diagnostics company, today announced two key leadership appointments. Dr Allan Brown has been appointed Chief Operating Officer and David Matthews joins as Chief Financial Officer.
These appointments represent the final parts of the transformation of QuantuMDxs Board, Executive and Senior Management teams, says CEO Elaine Warburton, OBE. We are now on a trajectory to successfully commercialise our technologies.
Dr Allan Brown joins QuantuMDx at a crucial time as he will help lead the launch of Q-POC, the companys pioneering portable diagnostics laboratory, which will compete on speed, price, simplicity of use and, importantly, mass multiplexing.
Allan joins from Genedrive Plc where, asChief Operating Officer and Board Director, his key successes included overseeing the market launch of Genedrive, a portable PCR platform used to diagnose HCV.
Throughout his career, Allan has worked for key players such as Qiagen and Tepnel Life Sciences Plc, covering product development through to commercial product launch, sales and business development and M&A.
I have long admired Allans innate ability to seamlessly move a companys operations from research through productization and into commercialisation whilst retaining a companys work ethos and personality, comments Elaine Warburton. Now QuantuMDx has prototypes in field studies across various continents testing assays in HPV genotyping, warfarin sensitivity genotyping and TB, having Allans experience will be a major factor in helping the Board drive commercial success.
Allan says, Ive been an avid follower of developments at QuantuMDx for a number of years and Im excited to be joining the team at such an important stage in the companys growth. The strength and applicability of the underlying technology combined with the passion and commitment of the people has been a key driver in my decision to join.
Joining as Chief Financial Officer, David Matthews brings over 30 years experience in life sciences, including strategic planning and operational execution to QuantuMDx. Formerly, David was CFO at Contextual Genomics, an oncology-focused diagnostics company in Vancouver, and as part of the founding team at GenomeDx Biosciences Inc, a molecular diagnostics company where he oversaw the companys growth from 20 to150 staff, and was closely involved in the launch of its first product, Decipher including obtaining coverage from Medicare and various private payers.
David is a specialist in taking companies at our stage of development through periods of rapid growth, into commercialisation, says Elaine Warburton.
Davids first priority at QuantuMDx will be to build investor engagement and raise significant growth capital for scale-up and manufacture. With a track record of raising over $500M of capital in private and public transactions, its a challenge he relishes.
David says, Im excited about joining this outstanding team and helping support the development of QuantuMDxs next generation in point of care testing.